GMAB Maintained at Buy by Deutsche Bank, May 2026

Deutsche Bank kept its Buy rating on Genmab A/S (GMAB) on May 11, 2026, but trimmed its price target. The analyst firm lowered the target to DKK 2,250 from DKK 2,400, signaling caution despite maintaining conviction. GMAB trades at $26.18 with a market cap of $16.1 billion. The biotech company develops antibody therapeutics for cancer and other diseases. This GMAB analyst rating adjustment reflects near-term headwinds in the sector while preserving long-term confidence in the company’s pipeline and market position.

Deutsche Bank Maintains GMAB Buy Rating with Lower Price Target

Rating Action and Price Target Adjustment

Deutsche Bank held its Buy rating on Genmab but reduced its price target by 150 DKK, moving from DKK 2,400 to DKK 2,250. This adjustment reflects a more cautious near-term outlook while preserving the positive long-term thesis. The price target lowering at Deutsche Bank came as the stock declined 0.65% on the day of the announcement. GMAB currently trades at $26.18, down 0.94% on the day, with a 52-week range of $18.89 to $35.43.

Analyst Consensus Strength

Genmab maintains strong analyst support with 13 Buy ratings and zero Sell or Hold ratings in the consensus. This unanimous bullish stance underscores confidence in the company’s antibody therapeutic pipeline. The consensus score of 4.00 reflects maximum conviction among tracked analysts. Despite the price target cut, Deutsche Bank’s maintained Buy rating signals that the company’s fundamentals remain intact for long-term investors.

Genmab’s Financial Position and Meyka Grade

Strong Profitability Metrics

Genmab demonstrates solid financial health with a P/E ratio of 6.15 and net profit margin of 29.6%. The company generated $14.40 in revenue per share and $4.26 in net income per share on a trailing twelve-month basis. Operating margin stands at 36.3%, reflecting efficient cost management in drug development. Free cash flow per share reached $1.87, supporting the company’s R&D investments and strategic partnerships.

Meyka AI Stock Grade

Meyka AI rates GMAB with a grade of B+, reflecting balanced fundamentals and market positioning. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score of 73.03 suggests the stock offers reasonable value for growth-oriented biotech investors. These grades are not guaranteed and we are not financial advisors.

Genmab’s Pipeline and Market Dynamics

Core Product Portfolio

Genmab’s revenue engine includes DARZALEX for multiple myeloma, teprotumumab for thyroid eye disease, and ofatumurnab for chronic lymphocytic leukemia. The company also markets Amivantamab for gastric, esophageal, and lung cancers. These approved therapies generate consistent revenue while the company advances 20 active pre-clinical programs. Strategic partnerships with Seagen, AbbVie, and Janssen strengthen development capabilities and market reach.

Recent Performance and Headwinds

Genmab’s stock has declined 15% year-to-date and 37.6% over three years, reflecting sector-wide biotech volatility. Revenue growth contracted 82% year-over-year, and net income fell 87%, signaling near-term challenges. However, the company maintains strong liquidity with a current ratio of 2.18 and minimal dividend obligations. The debt-to-equity ratio of 0.94 remains manageable for a biotech firm investing heavily in R&D.

Technical Outlook and Valuation Considerations

Technical Signals

Genmab’s technical indicators show mixed momentum. The RSI of 41.48 suggests the stock is neither overbought nor oversold. The MACD histogram remains negative at -0.07, indicating downward pressure. The Awesome Oscillator at -0.25 and Williams %R at -71.09 signal weakness. However, the stock trades within Bollinger Bands, suggesting consolidation rather than breakdown risk. Volume remains elevated at 2.6 million shares daily, above the 2.1 million average.

Valuation and Growth Prospects

At a P/E of 6.15, GMAB trades at a discount to biotech peers despite strong profitability. The price-to-sales ratio of 1.82 reflects reasonable valuation for a company with $14.40 in annual revenue per share. Meyka AI forecasts GMAB reaching $34.68 within one year and $56.19 within five years, suggesting 32% and 115% upside respectively. These projections assume successful pipeline advancement and market expansion.

Final Thoughts

Deutsche Bank maintains a Buy rating on Genmab despite reducing its price target from DKK 2,400 to DKK 2,250, reflecting confidence in the company’s antibody therapeutic strategy amid near-term challenges. With 13 Buy ratings in consensus, strong profitability, and a solid cash position, GMAB offers balanced risk-reward for biotech investors. The diverse pipeline and $16.1 billion market cap provide downside protection. Upcoming August 6, 2026 earnings will clarify revenue trends and pipeline progress, presenting a selective opportunity for long-term investors.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.